Search results for: “AMGN”
-
Amgen Inc Valuation – March 2019 #AMGN
Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.
-
Amgen Inc Valuation – June 2018 $AMGN
Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.
-
Amgen Inc Valuation – March 2017 $AMGN
Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.
-
Amgen Inc Valuation – August 2016 $AMGN
Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.
-
Amgen Inc Valuation – February 2016 $AMGN
Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PB ratio.
-
Amgen Inc. Analysis – September 2015 Update $AMGN
Amgen Inc. qualifies for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the short dividend history and high PEmg and PB ratios. The Enterprising Investor has no initial concerns.
-
Amgen Inc. Analysis – June 2015 Update $AMGN
Amgen performs well in the ModernGraham model and is suitable for Enterprising Investors. The Defensive Investor is concerned with the low current ratio, along with the poor PEmg and PB ratios, while the Enterprising Investor has no initial concerns.
-
Amgen Inc. Quarterly Valuation – March 2015 $AMGN
Amgen Inc. passes all of the initial requirements of the Enterprising Investor but not the more conservative Defensive Investor, who is concerned about the short dividend history along with the high PEmg and PB ratios.
-
Amgen Inc. Quarterly Valuation – December 2014 $AMGN
Amgen is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the short dividend history as well as the high PEmg and PB ratios.
-
Amgen Inc. Quarterly Stock Valuation – September 2014 $AMGN
Amgen Inc. qualifies for the Enterprising Investor but not the Defensive Investor. The Defensive Investor is concerned with the short dividend history as well as the high PEmg and PB ratios.